Llwytho...
Recent advances in theranostics and challenges for the future
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotat...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Br J Radiol |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
The British Institute of Radiology.
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475948/ https://ncbi.nlm.nih.gov/pubmed/29565650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1259/bjr.20170893 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|